Sebia receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices

Apr. 11, 2024

The next generation instrument for screening hemoglobin disorders in newborns.

Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays

Mrz. 06, 2024

Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.

Sebia launches M-inSight®, a test for monitoring multiple myeloma patients

Dez. 04, 2023

Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma

Sebia acquires Zeus Scientific

Okt. 12, 2022

The strategic acquisition reinforces Sebia’s product portfolio & strategy in autoimmunity

Sebia Acquires Orgentec Diagnostika

Jun. 29, 2021